Read by QxMD icon Read

Cardiovascular Drugs and Therapy

D Lanéelle, O Stivalet, G Mahé, V Jaquinandi, L Omarjee
No abstract text is available yet for this article.
July 9, 2018: Cardiovascular Drugs and Therapy
Hiroyuki Takahama, Masanori Asakura, Yukio Abe, Masayoshi Ajioka, Kazutaka Aonuma, Toshihisa Anzai, Takaharu Hayashi, Shinya Hiramitsu, Hiroya Kawai, Hidetaka Kioka, Kazuo Kimura, Young-Jae Lim, Ken Matsuoka, Hirohiko Motoki, Yoji Nagata, Sunao Nakamura, Nobuyuki Ohte, Yukio Ozaki, Taishi Sasaoka, Shunsuke Tamaki, Toshimitsu Hamasaki, Masafumi Kitakaze
BACKGROUND: Previous studies suggest that the pathophysiology of heart failure with preserved ejection fraction (HFpEF) is characterized not only by high ventricular stiffness, but also by vascular stiffness. Azilsartan has higher vascular affinity compared with other angiotensin II receptor blockers (ARBs), which were proven to have no beneficial effects on clinical outcomes in patients with HFpEF in earlier clinical trials. We aimed to test the hypothesis that azilsartan may improve left ventricular diastolic function in HFpEF patients with hypertension in this trial...
July 5, 2018: Cardiovascular Drugs and Therapy
Su Hyun Kim, Jang Hyun Cho, Yoon Ho Lee, Ji Hye Lee, Soo Sung Kim, Mi Yang Kim, Min Gu Lee, Won Yu Kang, Kyung Sim Lee, Young Keun Ahn, Myung Ho Jeong, Hyun Soo Kim
BACKGROUND/AIMS: The progression and development of congestive heart failure is still considered a large problem despite the existence of revascularization therapies and optimal, state-of-the-art medical services. An acute myocardial infarction (AMI) is a major cause of congestive heart failure, so researchers are investigating techniques to complement primary percutaneous coronary intervention (PCI) or thrombolytic therapy to prevent congestive heart failure after AMI. METHODS: Twenty-six patients with successful PCI for acute ST-segment elevation anterior wall myocardial infarction were assigned to either a control group (n = 12) or a bone marrow mesenchymal stem cells (BM-MSC) group (n = 14)...
June 28, 2018: Cardiovascular Drugs and Therapy
Hani N Sabbah, Ramesh C Gupta, Vinita Singh-Gupta, Kefei Zhang, David E Lanfear
PURPOSE: Abnormalities of MITO dynamics occur in HF and have been implicated in disease progression. This study describes the broad range abnormalities of mitochondrial (MITO) dynamics in Heart Failure with reduced ejection fraction (HF) and evaluates the effects of long-term therapy with elamipretide (ELAM), a MITO-targeting peptide, on these abnormalities. METHODS: Studies were performed in left ventricular tissue from dogs and humans with HF, and were compared with tissue from healthy dogs and healthy donor human hearts...
June 27, 2018: Cardiovascular Drugs and Therapy
Vijayapraveena Paruchuri, Juan Gaztanaga, Vikash Rambhujun, Robin Smith, Michael E Farkouh
Cardiovascular disease is the leading cause of death in men and women in the USA. Once a patient experiences an acute coronary syndrome (ACS), they are at increased risk for hospital readmission within 30 days and 6 months after discharge and more importantly, they have worse survival. Hospital readmissions lead to poor clinical outcomes for the patient and also significantly increase healthcare costs due to repeat diagnostic evaluation, imaging, and coronary interventions. The goal after hospital discharge is to modify cardiovascular (CV) risk factors including hypertension, hyperlipidemia, and diabetes to prevent repeat coronary events; however, drug therapy is only one aspect...
June 13, 2018: Cardiovascular Drugs and Therapy
Norihide Fukushima, Eisuke Tatsumi, Osamu Seguchi, Yoshiaki Takewa, Toshimitsu Hamasaki, Kaori Onda, Haruko Yamamoto, Teruyuki Hayashi, Tomoyuki Fujita, Junjiro Kobayashi
BACKGROUND: The management of heart failure patients presenting in a moribund state remains challenging, despite significant advances in the field of ventricular assist systems. Bridge to decision involves using temporary devices to stabilize the hemodynamic state of such patients while further assessment is performed and a decision can be made regarding patient management. The purpose of this study (NCVC-BTD_01, National Cerebral and Cardiovascular Center-Bridge to Dicision_01) is to assess the safety and effectiveness of the newly developed extracorporeal continuous-flow ventricular assist system employing a disposable centrifugal pump with a hydrodynamically levitated bearing (BR16010) use as a bridge-to-decision therapy for patients with severe heart failure or refractory cardiogenic shock...
June 8, 2018: Cardiovascular Drugs and Therapy
Angshuman Maulik, Sean M Davidson, Izabela Piotrowska, Malcolm Walker, Derek M Yellon
PURPOSE: Anthracyclines cause chronic irreversible cardiac failure, but the mechanism remains poorly understood. Emerging data indicate that cardiac damage begins early, suggesting protective modalities delivered in the acute stage may confer prolonged benefit. Ischaemic preconditioning (IPC) activates the pro-survival reperfusion injury salvage kinase (RISK) pathway which involves PI3-kinase and MAPK/ERK1/2. METHODS: We investigated whether simulated IPC (sIPC), in the form of a sublethal exposure to a hypoxic buffer simulating ischaemic conditions followed by reoxygenation, protects primary adult rat cardiomyocytes against anthracycline-induced injury...
May 15, 2018: Cardiovascular Drugs and Therapy
Ioannis Andreou, Alexandros Briasoulis, Christos Pappas, Ignatios Ikonomidis, Dimitrios Alexopoulos
PURPOSE: Clopidogrel is the standard P2Y12 receptor inhibitor used in patients requiring both antiplatelet therapy and oral anticoagulation (OAC). We investigated the safety and efficacy of ticagrelor as an alternative to clopidogrel in patients on OAC. METHODS: A systematic electronic literature search was performed in MEDLINE, EMBASE, and the Cochrane Library for randomised controlled studies that examined the relative safety and efficacy of clopidogrel versus ticagrelor among patients requiring therapy with antiplatelet agents plus OAC...
May 15, 2018: Cardiovascular Drugs and Therapy
Marian Goicoechea, Soledad García de Vinuesa, Borja Quiroga, Eduardo Verde, Carmen Bernis, Enrique Morales, Gema Fernández-Juárez, Patricia de Sequera, Ursula Verdalles, Ramón Delgado, Alberto Torres, David Arroyo, Soraya Abad, Alberto Ortiz, José Luño
BACKGROUND: Patients with chronic kidney disease (CKD) are at high risk for developing cardiovascular events. However, limited evidence is available regarding the use of aspirin in CKD patients to decrease cardiovascular risk and to slow renal disease progression. STUDY DESIGN: Prospective, multicenter, open-label randomized controlled trial. SETTING AND PARTICIPANTS: One hundred eleven patients with estimated glomerular filtration rate (eGFR) 15-60 ml/min/1...
June 2018: Cardiovascular Drugs and Therapy
Silvia Calabria, Emanuele Forcesi, Letizia Dondi, Antonella Pedrini, Aldo Pietro Maggioni, Nello Martini
PURPOSE: This observational study was aimed to identify patients who experienced non-deferrable surgery and/or uncontrolled severe bleeding following dabigatran administration and then are potentially eligible to the use of the specific antidote idarucizumab in a real-world setting. METHODS: From the big Italian real-world database ARCO, a cohort of adult patients treated with dabigatran and hospitalized due to diagnoses attributable to urgent interventions and/or major bleeding was selected in 2014...
June 2018: Cardiovascular Drugs and Therapy
Susan H Boklage, Elisabetta Malangone-Monaco, Lorena Lopez-Gonzalez, Yao Ding, Caroline Henriques, Joseph Elassal
PURPOSE: High-intensity statins (HIS) are recommended by current treatment guidelines for patients with clinical atherosclerotic cardiovascular disease and should be administered soon after an acute coronary syndrome (ACS) event and maintained thereafter. However, adherence to guidelines remains adequate. Statin utilization patterns during index hospitalization and the first year after ACS event, and the association between statin utilization and post-discharge clinical and economic outcomes, are described...
June 2018: Cardiovascular Drugs and Therapy
Qinzhong Chen, Robert S Rosenson
Lower extremity peripheral arterial disease (LEAD) is increasing in prevalence in low with approximately 202 million people affected with LEAD worldwide. Certain subgroups of individuals (cigarette smokers, diabetics) that are particularly high risk for LEAD and major adverse limb events (MALE). Conventionally, the ankle-brachial index (ABI) is the recommended screening test for LEAD. However, the ABI has several limitations, particularly in patients with diabetes. These limitations include increased measurement variability with severity of LEAD, non-compressible calcified arteries inability to detect arterial disease distal to the ankle precludes assessment of disease in the foot where many ulcers can occur, and underestimation of the extent of microvascular occlusive disease...
June 2018: Cardiovascular Drugs and Therapy
Richard Ofori-Asenso, Jenni Ilomäki, Ella Zomer, Andrea J Curtis, Sophia Zoungas, Danny Liew
BACKGROUND: Statins have become standard of care in the prevention and treatment of atherosclerotic cardiovascular disease. The objective of this study was to examine the trends in statin use among Australians aged ≥ 65 years for the period 2007-2016. METHODS: Data from the Pharmaceutical Benefits Scheme covering a 10% random sample of the Australian population were analysed. The 1-year prevalence and incidence of statin use were determined for each year, as were the percentage of statin dispensations according to statin type or intensity and the percentage of new users prescribed each statin type or intensity...
June 2018: Cardiovascular Drugs and Therapy
Xianliang Wang, Zhiqiang Zhao, Yazhu Hou, E Tang, Guoyuan Zhao, Shuai Wang, Yingfei Bi, Chengliang Zhong, Ming Ren, Junhua Zhang, Jingyuan Mao, Boli Zhang
BACKGROUND: Heart failure (HF) is the end stage of many heart diseases, and ischemic heart disease (IHD) is the primary cause. Yiqi Fumai lyophilized injection, a contemporary Chinese medicine preparation, widely used in the treatment of IHF patients, shows clinical efficacy on improving symptoms and cardiac function, but the quality of the current literature does not address multiple important issues. This article describes a protocol for assessment of complementary treatment with Yiqi Fumai lyophilized injection in acute decompensated IHD...
June 2018: Cardiovascular Drugs and Therapy
Harold E Bays, Robert S Rosenson, Marie T Baccara-Dinet, Michael J Louie, Desmond Thompson, G Kees Hovingh
The original version of this article unfortunately contained a mistake in the Discussion section.
April 2018: Cardiovascular Drugs and Therapy
Soo-Sang Kang, Robert S Rosenson
Homocysteine is an intermediary metabolite in the methionine cycle. Accumulation of homocysteine is caused either by mutation of relevant genes or by nutritional depletion of related vitamin(s). This review covers the historical background of hyperhomocysteinemia in which indispensable subjects in relation to underlying pathophysiological processes are discussed with the view of metabolism and genetics of folate and methionine cycles. This review emphasizes the unique role of homocysteine that is clearly distinct from other risk factors, particularly cholesterol in the development of vascular disease...
April 2018: Cardiovascular Drugs and Therapy
Eduardo Flores, Carlos G Santos-Gallego, Nely Diaz-Mejía, Juan Jose Badimon
Type 2 diabetes mellitus (T2DM) is one of the most common chronic health conditions in the USA; it affects approximately 10% of adults with up to one-quarter being undiagnosed. T2DM is associated with substantial cardiovascular (CV) morbidity and mortality. T2DM is a pathological condition characterized by elevated levels of glucose and associated with high CV risk. Traditional hypoglycemic drugs have demonstrated their capability for effective and maintained management of high glucose levels, but they have not significantly impacted on the incidence of CV events...
April 2018: Cardiovascular Drugs and Therapy
Liesa K Hoppe, Dana C Muhlack, Wolfgang Koenig, Prudence R Carr, Hermann Brenner, Ben Schöttker
PURPOSE: To provide the first systematic review and meta-analysis of observational studies on the association of abnormal serum potassium and cardiovascular outcomes. METHODS: Medline and ISI Web of Knowledge were systematically searched from inception until November 24, 2017. Data synthesis of relevant studies was performed using random effects model meta-analyses. RESULTS: Meta-analyses included 310,825 participants from 24 studies. In the older general population, low serum potassium was associated with a 1...
April 2018: Cardiovascular Drugs and Therapy
Ioanna Xanthopoulou, Vasiliki-Maria Dragona, Periklis Davlouros, Costas Tsioufis, Efstathios Iliodromitis, Dimitrios Alexopoulos
BACKGROUND: Approximately 5 to 7% of patients undergoing percutaneous coronary intervention (PCI) for the treatment of coronary artery disease require chronic oral anticoagulation (OAC) on top of aspirin and a P2Y12 receptor antagonist, mainly due to non-valvular atrial fibrillation (AF). The advent of non-vitamin K antagonist oral anticoagulants (NOACs) increased treatment options, while there is cumulative evidence that dual combination of a NOAC and a P2Y12 receptor antagonist attenuates risk of bleeding, compared to traditional triple therapy, consisting of a vitamin K antagonist (VKA), aspirin, and a P2Y12 receptor antagonist, without significantly compromising efficacy...
April 2018: Cardiovascular Drugs and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"